Oncology Business Management | Specialty

OncLive's 2015 Giants of Cancer Care Awards Announced

May 30th 2015

Twelve of the nation's leading oncology physicians, researchers and academicians were recognized by their peers as the 2015 Giants of Cancer Care at a ceremony hosted by OncLive at the Chicago Illuminating Company last night. The awardees included medical pioneers selected by a panel of eminent oncologists for landmark achievements in translational research, gene therapy, immuno-oncology and other groundbreaking work that has changed the course of cancer treatment.

Mismatch Repair a Potential Biomarker for PD-1 Inhibition

May 29th 2015

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

OncLive's 2015 Giants of Cancer Care Awards Announced Today

May 29th 2015

OncLive proudly announces the 2015 Giants of Cancer Care, a dozen medical pioneers recognized by a panel of eminent oncologists for landmark achievements that have changed the course of cancer treatment. Honorees will be introduced and celebrated at the 3rd Annual Giants of Cancer Care Award Ceremony, held 8:30-11:00 p.m. CDT at The Chicago Illuminating Company.

ASCO Proposes New Physician Payment Reforms

May 21st 2015

ASCO has proposed a series of payment reforms that it says would significantly increase physician pay and the breadth of patient services available while lowering the overall cost of cancer care.

Announcement of OncLive's 2015 Giants of Cancer Care Honorees Advances Legacy of Groundbreaking Treatment, Research

May 20th 2015

Oncologists whose research and treatment innovations have changed the course of cancer care will join the elite roster of medical pioneers named OncLive's Giants of Cancer Care when the 2015 honorees are announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.

Proteoglycan Assay Shows Potential as Adjunct to PSA Measurement

May 18th 2015

A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.

Bone Metastases in CRPC: Prognostic for Survival

May 17th 2015

Biomarkers Indicative of Bone Lesions in Prostate Cancer

May 17th 2015

Asymptomatic Versus Symptomatic Bone Metastases in Prostate Cancer

May 17th 2015

Symptomatic Bone Lesions in CRPC: More Options for Treatment

May 17th 2015

Reducing Skeletal-Related Events in Prostate Cancer

May 17th 2015

Administering Radium-223 for mCRPC

May 17th 2015

Reassessing Trial Endpoints for CRPC

May 17th 2015

AUA2015: Biomarkers, Enzalutamide, and ARN509

May 17th 2015

Combining and Sequencing Sipuleucel-T in CRPC

May 17th 2015

Committee of Elite Oncologists Selects World's Best to Receive OncLive's 2015 Giants of Cancer Care Awards

May 14th 2015

Individuals chosen by this elite committee to receive the 2015 Giants of Cancer Care award for outstanding contributions in the field of oncology will be announced Friday, May 29, during the 3rd Annual Giants of Cancer Care Award Ceremony.

Doctors Unwilling to Trust Similarity of Biosimilars

May 13th 2015

The FDA's approval in March of the first biosimilar drug for the US market has aroused much concern among physicians.

Doctors May Lose Care Control to Integrated Delivery Networks

May 9th 2015

The healthcare market has been consolidating in recent years with practice mergers, hospital partnerships, and acquisitions or affiliations with primary care and specialist practices.

First FDA-Approved Biosimilar Blocked From Entering US Market

May 8th 2015

The first FDA-approved biosimilar, Zarxio, has been blocked from reaching US markets by an injunction from Amgen, the manufacturer of the G-CSF analog counterpart, Neupogen (filgrastim).

FDA Grants Venetoclax Breakthrough Designation for CLL

May 7th 2015

The FDA has granted a breakthrough therapy designation to the Bcl-2 inhibitor venetoclax (GDC-0199/ABT-199) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who harbor a 17p deletion (del[17p]).